MSD’s Cozaar and AstraZeneca/Takeda’s Amias maintain their respective first and second positions in the chart – the same slots they held in the previous anti-hypertensives chart in November last year.
But GP awareness of Diovan has fallen by one per cent to 87 per cent since last time round, while Aprovel has risen from 84 per cent to 88 per cent.
Awareness of BMS/Sanofi’s CoAprovel has surged ten per cent and moves up a place to fifth, knocking Boehringer Ingelheim’s Micardis (53 per cent to 55 per cent) down one slot.
In respect of the likelihood of GPs prescribing each drug as a result of promotional messages, Cozaar has fallen five per cent to 44 per cent.
Amias, however, has rocketed from 28 per cent to 42 per cent, and Aprovel has risen seven per cent to 37 per cent.
There are two new entrants to the table this time – Sankyo’s Olmetec and Solvay’s new brand Teveten. GP awareness of both products stands at 35 per cent.
Two-hundred GPs were surveyed online by NOP World Health via GP Net Surveys.
NOP World Health senior research executive Jude Ryall said: ‘Cozaar and Amias are clearly the products within the AIIA [angiotensin-II-antagonist] group best regarded by GPs.’
NEXT MONTH: Migraine treatments